Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OHB-607 versus standard neonatal care for prevention of severe bronchopulmonary dysplasia in extremely premature infants
NL-OMON59599Phase 2Active, not recruiting
- Sponsor
- Ohb Neonatology Limited
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Premiplex in bronchopulmonary dysplasia (BPD), sponsored by Ohb Neonatology Limited. Primary endpoint: Incidence of severe bronchopulmonary dysplasia or death by 36 weeks postmenstrual age. Started Oct 2024; status: active, not recruiting.
02
Drugs
Premiplex
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NL-OMON59599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59599.